SCHEMBL211599

SCHEMBL211599

CCCNCCOC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9731501 0.97
SCHEMBL11119 0.87
SCHEMBL17992469 0.85 KDM4E (0.50)
SCHEMBL19478680 0.85 KDM4E (0.50)
SCHEMBL22856501 0.85 KDM4E (0.50)
SCHEMBL24508502 0.85 KDM4E (0.50)
SCHEMBL18467834 0.85 KDM4E (0.50)
SCHEMBL22802914 0.85 KDM4E (0.50)
SCHEMBL3631301 0.84 KDM4E (0.42)
Fluoride SCHEMBL25246136 0.84 KDM4E (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233963-A Method for producing a plurality of monomers for preparing synthetic resins from fatty alcohols 安廷梧 2024-12-31 CN claimed
CN-118299662-A Low-temperature rechargeable magnesium battery electrolyte and preparation method and application thereof 重庆大学 2024-07-05 CN claimed
CN-117936901-A Rechargeable magnesium battery amine electrolyte and preparation method and application thereof 上海交通大学 2024-04-26 CN claimed
US-20210121397-A1 BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS ALLERGAN INC (US) 2021-04-29 US claimed
EP-3504210-B1 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2021-02-24 EP claimed
US-10881608-B2 Biodegradable intravitreal tyrosine kinase implants ALLERGAN, INC. (US) 2021-01-05 US claimed
EP-3008055-B1 TETRAZOLONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-07-19 EP claimed
EP-3008055-A1 NOVEL TETRAZOLONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2016-04-20 EP claimed
US-20160083357-A1 NOVEL TETRAZOLONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2016-03-24 US claimed
WO-2014198592-A1 NOVEL TETRAZOLONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-12-18 WO claimed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US claimed
WO-2005115089-A2 A PROCESS AND SYSTEM FOR PRINTING IMAGES ON ABSORPTIVE SURFACES KORNIT DIGITAL LTD. (IL) 2005-12-08 WO claimed
US-20040198802-A1 Kinase inhibitors for the treatment of disease ALLERGAN, INC. 2004-10-07 US claimed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US claimed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US claimed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 EP claimed
WO-2004050621-A2 INDOL DERIVATIVES AND THEIR USE AS KINASE INHIBITORS ALLERGAN, INC (US) 2004-06-17 WO claimed
US-20040102509-A1 KINASE INHIBITORS FOR THE TREATMENT OF DISEASE ALLERGAN, INC. 2004-05-27 US claimed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US claimed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO claimed